Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines

Abstract

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS, most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination in space and in time, and exclude alternative diseases that can explain the findings at hand. The differential diagnostic workup should be guided by clinical and laboratory red flags to avoid unnecessary tests. Appropriate selection of multiple sclerosis (MS) therapies is critical to maximize patient benefit. The current guidelines review the scientific evidence supporting treatment of acute relapses, radiologically isolated syndrome, clinically isolated syndrome, relapsing remitting MS, and progressive MS. The purpose of these guidelines is to provide practical recommendations and algorithms for the diagnosis and treatment of MS based on current scientific evidence and clinical experience. © 2019 Elsevier B.V.

Description

Keywords

Africa, northern, Consensus, Humans, Middle east, Multiple sclerosis, Practice guidelines as topic, Alemtuzumab, Beta interferon, Cladribine, Fingolimod, Fumaric acid dimethyl ester, Glatiramer, Immunoglobulin, Interleukin 1beta, Methylprednisolone, Natalizumab, Ocrelizumab, Peginterferon, Prednisone, Rituximab, Siponimod, Teriflunomide, Algorithm, Bradycardia, Breast feeding, Demyelinating disease, Diarrhea, Drug efficacy, Drug safety, Evidence based medicine, Hair disease, Human, Idiopathic thrombocytopenic purpura, Infection, Leukopenia, Lymphocytopenia, Macular edema, Nausea, Neurologist, Personal experience, Practice guideline, Pregnancy, Progressive multifocal leukoencephalopathy, Review, Side effect, Thyroid disease, Vomiting, Africa

Citation

Collections

Endorsement

Review

Supplemented By

Referenced By